Finance

Lists
Why is AKTS up २.३१%?
Dive Deeper
AKTS:NASDAQ
Aktis Oncology Inc
US$ १८.१५
+२.३१%
(+०.४१) 1D
US$ १८.१५
०.००% (०.००)
After hours
Closed: अक्टोबर ९, १६:००:०१ GMT-४  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for AKTS...
Open
US$ १७.७४
High
US$ १८.२१
Low
US$ १७.५८
Mkt. cap
९७.५५ करोड
Avg. vol.
४.२७ लाख
Volume
३.६१ लाख
52-wk high
US$ ३४.१९
52-wk low
US$ १४.७२
EPS
-US$ १.४२
Shares outstanding
५.३७ करोड
No. of employees
७९
Open
US$ १७.७४
High
US$ १८.२१
Low
US$ १७.५८
Mkt. cap
९७.५५ करोड
Avg. vol.
४.२७ लाख
Volume
३.६१ लाख
52-wk high
US$ ३४.१९
52-wk low
US$ १४.७२
EPS
-US$ १.४२
Shares outstanding
५.३७ करोड
No. of employees
७९
News stories
From web sources and news partners
About Aktis Oncology Inc
CEO-
Employees७९
Founded२०२०
Headquartersबोस्टन, म्यासेचुसेट्स, संयुक्त राज्य अमेरिका
Sector-
Analyst ratings
Based on 6 analysts giving stock ratings to AKTS in the past 3 months
Strong buy
Buy
6
Hold
0
Sell
0
12-month forecast
Based on 6 Wall Street analysts offering 12 month price targets for AKTS in the last 3 months.
Highest
Current US$ १८.१५
US$ ४०.०० (+१२०.३९%)
Average
US$ ३५.८० (+९७.२५%)
Lowest
US$ ३३.०० (+८१.८२%)
Analyst
Recommendation
Action
Price target
Projected
Date
David Nierengarten
Wedbush
Buy
Maintained
US$ ३५.००
+९२.८%
10/02/2026
Jeff Jones
Oppenheimer
Buy
Initiated
US$ ४०.००
+१२०.४%
09/09/2026
David Lebowitz
BMO Capital
Buy
Initiated
US$ ३७.००
+१०३.९%
08/18/2026
Unknown Analyst
BMO Capital
Buy
Initiated
US$ ३७.००
+१०३.९%
08/18/2026
Alec Stranahan
Bank of America Securities
Buy
Maintained
US$ ३४.००
+८७.३%
08/14/2026
Jessica Fye
J.P. Morgan
Buy
Reiterated
US$ ३३.००
+८१.८%
08/14/2026
Alexandra Ramsey
William Blair
Buy
Maintained
-
-
08/14/2026
Christopher Raymond
Raymond James
Buy
Initiated
US$ ४०.००
+१२०.४%
06/16/2026
Robert Burns
H.C. Wainwright
Buy
Reiterated
US$ ३५.००
+९२.८%
06/03/2026
Tyler Van Buren
TD Cowen
Buy
Maintained
-
-
05/11/2026
Sami Corwin
William Blair
Buy
Initiated
US$ १८.७५
+३.३%
05/02/2026
Unknown Analyst
William Blair
Buy
Initiated
US$ १८.६०
+२.५%
04/29/2026
Andy Hsieh
William Blair
Buy
Initiated
US$ ३२.००
+७६.३%
04/29/2026
Jonathan Chang
Leerink Partners
Buy
Initiated
US$ ३१.००
+७०.८%
02/03/2026
Last report
२०२६ अगस्ट १३
Fiscal period
Q2 2026
-US$ ०.४४ / -US$ ०.४३
-२.१५%miss
Revenue / Est. (USD)
३३.८४ लाख / २५.८३ लाख
+३०.९९%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
२०२५ जुन
२०२५ डिसेम्बर
२०२६ मार्च
२०२६ जुन
Revenue
१६.०१ लाख
१८.७० लाख
३२.२७ लाख
३३.८४ लाख
Cost of goods sold
१.८६ करोड
१.६५ करोड
२.०० करोड
२.५३ करोड
Cost of revenue
१.८६ करोड
१.६५ करोड
२.०० करोड
२.५३ करोड
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
३९.३६ लाख
२७.५२ लाख
५८.९७ लाख
७०.०३ लाख
Operating expense
३९.३६ लाख
२७.५२ लाख
५८.९७ लाख
७०.०३ लाख
Total operating expenses
२.२६ करोड
१.९२ करोड
२.५९ करोड
३.२३ करोड
Operating income
-२.१० करोड
-१.७४ करोड
-२.२७ करोड
-२.८९ करोड
Other non operating income
-२०.०० हजार
-११.०० हजार
-३.०० हजार
-१०.०० हजार
EBT including unusual items
-१.८१ करोड
-१.५१ करोड
-१.८३ करोड
-२.४१ करोड
EBT excluding unusual items
-१.८१ करोड
-१.५१ करोड
-१.८३ करोड
-२.४१ करोड
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-१.८१ करोड
-१.५१ करोड
-१.८३ करोड
-२.४१ करोड
Net profit margin
-१,१२८.९८%
-८०९.५२%
-५६७.८६%
-७१३.४८%
Earnings per share
-
-
-०.३८
-०.४४
Interest and investment income
२९.०८ लाख
२२.४८ लाख
४३.८४ लाख
४७.६५ लाख
Interest expense
-
-
-
-
Net interest expenses
२९.०८ लाख
२२.४८ लाख
४३.८४ लाख
४७.६५ लाख
Depreciation and amortization charges
-
-
-
-
EBITDA
-२.०४ करोड
-१.६७ करोड
-२.२१ करोड
-२.८० करोड
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
Google एपहरू